Last reviewed · How we verify
LP002
At a glance
| Generic name | LP002 |
|---|---|
| Sponsor | Taizhou HoudeAoke Biomedical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of HX008 Plus LP002 for the Treatment of Patients With Advanced Melanoma (PHASE1)
- A Study of LP002 for the Treatment of Patients With Malignant Digestive System Neoplasms (PHASE1)
- Study of LP002 in Combination With Chemotherapy for Patients With Extensive Stage Small Cell Lung Cancer (PHASE2)
- Study of LP002 for the Treatment of Patients With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LP002 CI brief — competitive landscape report
- LP002 updates RSS · CI watch RSS
- Taizhou HoudeAoke Biomedical Co., Ltd. portfolio CI